ReviewVirchows Archiv : an international journal of pathology2019
Recent advances in invasive adenocarcinoma of the cervix.
Review in Virchows Archiv : an international journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Association between Silva pattern-based classification and endocervical adenocarcinoma: a systematic review and meta-analysis.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Pooled it
- Invasive stratified mucin-producing carcinoma of the uterine cervix masquerading as squamous cell carcinoma on biopsy: a diagnostic pitfall.Oxford medical case reports · 2026Article
- Review
- Role of human papillomavirus status in the classification, diagnosis, and prognosis of malignant cervical epithelial tumors and precursor lesions.Pathologie (Heidelberg, Germany) · 2026Review
- Mesonephric Hyperplasia and Adenocarcinoma of the Cervix: A Rare Evolution, Case Report, and Review of the Literature.Reports (MDPI) · 2025Article
- The Epidemiology of Cervical Cancer in Germany: A Registry-Based Analysis of Incidence, Survival, and Tumor Characteristics (2003–2021).Deutsches Arzteblatt international · 2025Observational
- Prognostic Differences and Survival Predictive Models for Mucinous Versus Usual-Type Adenocarcinoma of the Uterine Cervix.Cancer medicine · 2025Article
- Endocervical adenocarcinomas and HPV genotyping in an HIV endemic milieu - a retrospective study.BMC women's health · 2025Article
- RCN1 Binds KIF14 and Promotes the Malignant Growth of Cervical Cancer Through the PI3K-AKT Pathway.International journal of general medicine · 2025Article
- Mapping the immunological landscape and emerging immunotherapeutic strategies in cervical cancer: a comprehensive review.Frontiers in oncology · 2025Review
- Trop2 expression, p16 expression status, and histologic subtype in carcinoma of the uterine cervix.Pathology oncology research : POR · 2025Article
- Hippo signaling pathway in cervical cancer: insights into mechanisms and therapeutic potential.Frontiers in oncology · 2025Review
- Development and validation of a nomogram for predicting survival in gastric signet ring cell carcinoma patients treated with radiotherapy.Scientific reports · 2024Article
- Contemporary Review of Adenocarcinoma of the Cervix.Current treatment options in oncology · 2024Review
- Primary cervical signet ring cell carcinoma: A rare case report and literature review.Gynecologic oncology reports · 2024Article
- Integrating MRI-based radiomics and clinicopathological features for preoperative prognostication of early-stage cervical adenocarcinoma patients: in comparison to deep learning approach.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Analysis of related factors for pathological upgrading of cervical biopsy from CIN3 to cancer after conical resection.BMC cancer · 2024Article
- Article
- PCDHGB7 hypermethylation-based Cervical cancer Methylation (CerMe) detection for the triage of high-risk human papillomavirus-positive women: a prospective cohort study.BMC medicine · 2024Article
- Disparities in Survival Outcomes Between Locally Advanced Cervical Squamous Cell Carcinoma and Adenocarcinoma Treated with Chemoradiotherapy.International journal of women's health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Endocervical adenocarcinomas (ECAs) are currently classified according to the 2014 World Health Organization (WHO) system, which is predominantly based on descriptive morphologic characteristics, considers factors bearing minimal etiological, clinical, or therapeutic relevance, and lacks sufficient reproducibility. The 2017 International Endocervical Adenocarcinoma Criteria and Classification (IECC) system was developed by a group of international collaborators to address these limitations. The IECC system separates ECAs into two major groups-those that are human papillomavirus-associated (HPVA) and those that are non-HPV-associated (NHPVA)-based on morphology (linked to etiology) alone, precluding the need for an expensive panel of immunohistochemical markers for most cases. The major types of HPVA ECA include the usual (with villoglandular and micropapillary architectural variants) and mucinous types (not otherwise specified [NOS], intestinal, signet-ring, and invasive stratified mucin-producing carcinoma). Invasive adenocarcinoma NOS is morphologically uninformative, yet considered part of this group when HPV positive. NHPVA ECAs include gastric, clear cell, endometrioid, and mesonephric types. The IECC system is supported by demographic and clinical features (HPVA ECAs develop in younger patients, are smaller, and are diagnosed at an earlier stage), p16/HPV status (almost all HPVA ECAs are p16 and/or HPV positive), prognostic parameters (NHPVA ECAs more often have lymphovascular invasion, lymph node metastases, and are Silva pattern C), and survival data (NHPVA ECAs are associated with worse survival). A move from the morphology-based WHO system to the IECC system will likely provide clinicians with an improved means to diagnose and classify ECAs, and ultimately, to better personalize treatment for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.